An Open Label, Study of the Systemic Exposure to Articaine After Topical Ocular Dosing of AG-920
Completed · Phase 1
Conditions studied: Healthy
In brief
This is a Phase 1, open-label, non-comparative study in healthy subjects performed in the US. It is designed to assess systemic exposure to articaine and its metabolite articainic acid after dosing a single topical ocular administration of AG-920 in the randomized study eye.
Key facts
- Study ID
- NCT04759339
- Run by
- American Genomics, LLC
- People needed
- 14
- Starts
- 2021-02-24
- Expected to finish
- 2021-02-25
- Last updated by the study team
- 2022-04-29
Who can join
Age: 19 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- Celerion — Lincoln, Nebraska, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.